electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19

    NEXT STORY
    Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
    PREV STORY
    Prolacta Bioscience Reassures Hospitals of the Safety of Its Human Milk-Based Nutritional Products During the Coronavirus Pandemic
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Lilly dévoile des données de validation de principe concernant l’anticorps neutralisant LY-CoV555 pour le traitement de la COVID-19 en contexte ambulatoire

    author_avatar
    NASDAQ Market News

    ABLYNX WILL ANNOUNCE ITS 2017 HALF YEAR RESULTS WITH WEBCAST ON 24 AUGUST 2017

    GHENT, Belgium, 17 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report ...

    author_avatar
    NASDAQ Market News

    Biodesix Announces PD-L1 Collaboration with Professor Fred R. Hirsch

    BOULDER, Colo., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Biodesix® announced a new collaboration agreement ...

    author_avatar
    NASDAQ Market News